SLC2A4 and cancer: Finally, the generated anticancer putative AMPs were used in this study to inhibits Slc2a4; an important protein that responsible for energy productions during angiogenesis in tumour formation and this can serve as another novel therapeutic agent for the treatment and management of cancer.